BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8827220)

  • 1. In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160.
    Pincus SH; Wehrly K; Cole R; Fang H; Lewis GK; McClure J; Conley AJ; Wahren B; Posner MR; Notkins AL; Tilley SA; Pinter A; Eiden L; Teintze M; Dorward D; Tolstikov VV
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):1041-51. PubMed ID: 8827220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.
    Pincus SH; Song K; Maresh GA; Hamer DH; Dimitrov DS; Chen W; Zhang MY; Ghetie VF; Chan-Hui PY; Robinson JE; Vitetta ES
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27852851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.
    Pincus SH; Cole RL; Hersh EM; Lake D; Masuho Y; Durda PJ; McClure J
    J Immunol; 1991 Jun; 146(12):4315-24. PubMed ID: 1710247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus.
    Pincus SH; McClure J
    Proc Natl Acad Sci U S A; 1993 Jan; 90(1):332-6. PubMed ID: 8419938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of endosome-destabilizing peptides on efficacy of anti-HIV immunotoxins.
    Tolstikov VV; Cole R; Fang H; Pincus SH
    Bioconjug Chem; 1997; 8(1):38-43. PubMed ID: 9026033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection.
    Pincus SH; Fang H; Wilkinson RA; Marcotte TK; Robinson JE; Olson WC
    J Immunol; 2003 Feb; 170(4):2236-41. PubMed ID: 12574398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain.
    Till MA; Zolla-Pazner S; Gorny MK; Patton JS; Uhr JW; Vitetta ES
    Proc Natl Acad Sci U S A; 1989 Mar; 86(6):1987-91. PubMed ID: 2538826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal idiotypic and anti-idiotypic antibodies to human immunodeficiency virus type 1 envelope glycoprotein.
    Brodeur BR; Faucher S; O'Shaughnessy MV; Hamel J
    J Gen Virol; 1991 Jan; 72 ( Pt 1)():51-8. PubMed ID: 1703562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.
    Sattentau QJ; Zolla-Pazner S; Poignard P
    Virology; 1995 Jan; 206(1):713-7. PubMed ID: 7530400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective killing of HIV-infected cells by anti-gp120 immunotoxins.
    Matsushita S; Koito A; Maeda Y; Hattori T; Takatsuki K
    AIDS Res Hum Retroviruses; 1990 Feb; 6(2):193-203. PubMed ID: 2328157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin.
    Pincus SH; Wehrly K; Tschachler E; Hayes SF; Buller RS; Reitz M
    J Exp Med; 1990 Sep; 172(3):745-57. PubMed ID: 1696955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies.
    Peachman KK; Wieczorek L; Polonis VR; Alving CR; Rao M
    Virology; 2010 Dec; 408(2):213-23. PubMed ID: 20961591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.
    Pincus SH; Song K; Maresh GA; Frank A; Worthylake D; Chung HK; Polacino P; Hamer DH; Coyne CP; Rosenblum MG; Marks JW; Chen G; Weiss D; Ghetie V; Vitetta ES; Robinson JE; Hu SL
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27795412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells.
    Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG
    Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
    Stiegler G; Kunert R; Purtscher M; Wolbank S; Voglauer R; Steindl F; Katinger H
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1757-65. PubMed ID: 11788027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for the use of immunotoxins in the treatment of HIV-infected humans.
    Van Oijen MG; Preijers FW
    J Drug Target; 1998; 5(2):75-91. PubMed ID: 9588864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant antibodies with conformationally constrained HIV type 1 epitope inserts elicit glycoprotein 160-specific antibody responses in vivo.
    Cook J; Barber BH
    AIDS Res Hum Retroviruses; 1997 Apr; 13(6):449-60. PubMed ID: 9100986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.